ACXP

Acurx Pharmaceuticals, Inc.
CAPPED RATING

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc. (ACXP) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.5
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -35.1%
Price Return 12M -80.3%
Catalyst Signal 0.00
Market Cap $5.7M
TTM Revenue N/A
Price / Sales N/A
ROE -147.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) C- (2.0) D (1.5) D+ (1.5) C+ (2.6) C- (2.0)
2026-11-10 C+ (2.5) C- (2.0) C+ (2.7) D+ (1.6) C+ (2.6) C (2.3)
2026-11-03 C+ (2.5) C- (1.9) C+ (2.7) D+ (1.7) C+ (2.7) C (2.3)
2026-10-27 C+ (2.5) C- (1.9) C+ (2.7) D+ (1.6) C+ (2.6) C (2.3)
2026-10-20 C+ (2.5) C- (1.9) C+ (2.7) D+ (1.5) C+ (2.6) C (2.3)
Page 1 of 4